Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates

Company Performance - Dare Bioscience, Inc. reported a quarterly loss of $0.45 per share, which was better than the Zacks Consensus Estimate of a loss of $0.55, representing an earnings surprise of +18.18% [1] - The company has surpassed consensus EPS estimates for the last four quarters, but it reported revenues of -$0.02 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 103.68% [2] - The stock has lost approximately 32.4% since the beginning of the year, contrasting with the S&P 500's gain of 10% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.52 on revenues of $0.59 million, and for the current fiscal year, it is -$1.99 on revenues of $1.67 million [7] - The estimate revisions trend for Dare Bioscience was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Dare Bioscience belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]